Business Context and Reporting Period
This Form 8-K Current Report was filed by aTyr Pharma, Inc. on November 1, 2017. The filing discloses a significant leadership transition within the company's executive management and board of directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and employment terms.
Material Changes
- CEO Transition: Sanjay S. Shukla, M.D., M.S., succeeded John D. Mendlein, Ph.D., as President and Chief Executive Officer effective November 1, 2017.
- Board Appointment: Dr. Shukla was appointed as a Class III director of the Board effective November 1, 2017.
- Outgoing CEO Role: Dr. Mendlein's last day as an employee is December 31, 2017. He will remain as a director and serve as a strategic advisor.
Compensation and Employment Terms
Dr. Sanjay S. Shukla (New CEO)
- Base Salary: $450,000 annually, subject to review.
- Annual Bonus Target: 45% of base salary for the remainder of 2017; 50% of base salary for subsequent years.
- Equity Grant: Option to purchase 450,000 shares of common stock effective November 1, 2017.
- Termination Benefits: Includes severance equal to one year of base salary plus target bonus, acceleration of vesting for options vesting within 12 months, and 12 months of health insurance coverage upon termination without Cause or for Good Reason.
- Change in Control: Triggers full acceleration of all outstanding stock options and a cash payment equal to 1.0 times base salary plus target bonus.
Dr. John D. Mendlein (Outgoing CEO/Advisor)
- Advisor Compensation: Monthly rate of $42,500 for the first year of the Strategic Advisor Agreement, decreasing to $7,500 per month for the remainder of the up-to-four-year term.
- Benefits: Reimbursement for benefits continuation through December 31, 2018, and continued vesting of outstanding time-based stock options while providing services.
- Change in Control: Triggers full acceleration of all outstanding time-based employee stock options.
Investor Verification Checklist
- Verify the full text of the CEO Employment Agreement and Strategic Advisor Agreement, which are intended to be filed as exhibits to the Form 10-Q for the period ending September 30, 2017.
- Confirm the specific definitions of "Good Reason" and "Change in Control" within the employment contracts to understand the triggers for severance and acceleration.
- Review the press release attached as Exhibit 99.1 for additional context on the strategic rationale for the leadership change.
- Monitor future filings for the impact of the new leadership on the company's clinical development pipeline and financial outlook.